GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next
London, Jan 14, 2026, 09:03 GMT — Regular session GSK shares rose in early London trade on Wednesday after Summit Therapeutics said it struck a clinical trial collaboration with the British drugmaker to test a new cancer combination. (MarketScreener) The move lands as investors look for signposts on how much growth GSK can squeeze from its oncology pipeline before it reports full-year results next month. GSK has pencilled in Feb. 4 for its full-year and fourth-quarter update. (GSK) Big drugmakers have been under pressure to refill pipelines as a wave of patent expiries looms for the industry, helping drive a